Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Chimeric Therapeutics Ltd. ( (AU:CHM) ) is now available.
Chimeric Therapeutics’ new chair has outlined a sharpened strategic focus built around its lead CHM CDH17 cell therapy program for advanced gastrointestinal cancers, following early Phase 1/2 data showing disease control in most evaluable patients and a notable case of prolonged stable disease after a single infusion. With the asset now backed by U.S. FDA Orphan Drug Designation for gastric cancer, the company is concentrating resources on this differentiated program while stressing disciplined interpretation of clinical signals.
As part of a broader governance and capital reset, Chimeric has returned its lower-priority CHM CLTX program to City of Hope, implemented targeted cost reductions, and shifted to a contract chief medical officer model to cut fixed expenses without disrupting the CHM CDH17 trial. The board is tying capital allocation to defined clinical milestones, aiming to extend runway and minimise dilution after securing new funding commitments and an R&D tax refund, while pledging to avoid non‑material market updates and focus disclosure on meaningful value inflection points for shareholders.
The most recent analyst rating on (AU:CHM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Chimeric Therapeutics Ltd. stock, see the AU:CHM Stock Forecast page.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd is a small-cap biotechnology company focused on developing cell therapies for solid tumours, particularly aggressive gastrointestinal cancers such as colorectal and gastric cancer. Its lead clinical program, CHM CDH17, targets the CDH17 biomarker and has received U.S. FDA Orphan Drug Designation in gastric cancer, positioning the company within a high-need oncology niche.
Technical Sentiment Signal: Sell
Current Market Cap: A$8.84M
Find detailed analytics on CHM stock on TipRanks’ Stock Analysis page.